Cargando…

Genetic variation of interleukin-1 receptor type 1 is associated with severity of COVID-19 disease

Detalles Bibliográficos
Autor principal:	Wang, Renxi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The British Infection Association. Published by Elsevier Ltd. 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690223/ https://www.ncbi.nlm.nih.gov/pubmed/34952040 http://dx.doi.org/10.1016/j.jinf.2021.12.010

Ejemplares similares

Genetic variation of allergic disease is associated with the susceptibility to COVID-19
por: Xu, Yaqi, et al.
Publicado: (2022)

Genetic variation associated with COVID-19 is also associated with endometrial cancer
por: Gao, Ran, et al.
Publicado: (2022)

Genetic variation of Golgi membrane protein 1 is associated with COVID-19 disease
por: Fu, Jiantao, et al.
Publicado: (2022)

DNA methylation signature of interleukin 1 receptor type II in asthma
por: Gagné-Ouellet, Valérie, et al.
Publicado: (2015)

Genetic variant in complement receptor 1 (CR1, CD35) is associated with a cluster of severe fatal COVID-19 in a family
por: Danial-Farran, N., et al.
Publicado: (2023)

Interleukin-6 and severity of COVID-19 patients in Hefei, China
por: Zhao, Z., et al.
Publicado: (2020)

Reply to ‘COVID‐19 severity, miR‐21 targets, and common human genetic variation’
por: Derda, Anselm A., et al.
Publicado: (2021)

Safety and efficacy of interleukin-1 antagonists in hospitalized patients with COVID-19
por: Dimosiari, Athina, et al.
Publicado: (2023)

Association of asthma and its genetic predisposition with the risk of severe COVID-19
por: Zhu, Zhaozhong, et al.
Publicado: (2020)

Potential effects of itolizumab treatment on plasma interleukin-6 levels in patients with severe COVID-19
por: Vityala, Yethindra, et al.
Publicado: (2021)

Genetic factors may affect the severity of COVID-19
por: Zheng, Zhenzhen, et al.
Publicado: (2021)

Clinical significance of genetic polymorphisms of interleukin-1β and cytochrome P450 2C19 on the eradication of Helicobacter pylori
por: Karbalaei, Mohsen, et al.
Publicado: (2023)

Comment on: ‘Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know?’
por: Kow, Chia Siang, et al.
Publicado: (2023)

Novel evidence revealed genetic association between COVID-19 infection, severity and endometrial cancer
por: Wu, Xiangrong, et al.
Publicado: (2022)

Association of blood type A with increased risk of severe COVID-19 in healthcare workers
por: Mahajan, Niraj N., et al.
Publicado: (2021)

Genetic emergence of B.1.617.2 in COVID-19
por: Kirola, L.
Publicado: (2021)

Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer
por: Zhang, Yang, et al.
Publicado: (2022)

Dementia is Associated with Severe Coronavirus Disease 2019 (COVID-19) Infection
por: Hariyanto, Timotius Ivan, et al.
Publicado: (2021)

Genetic predisposition to allergic diseases is inversely associated with risk of COVID‐19
por: Larsson, Susanna C., et al.
Publicado: (2021)

Interleukin-6 as a potential biomarker of COVID-19 progression
por: Ulhaq, Zulvikar Syambani, et al.
Publicado: (2020)

Interleukin-17: A potential therapeutic target in COVID-19
por: Mendoza, Vicky M. Montaño
Publicado: (2020)

Interleukin-1 gene cluster polymorphisms associated with coronary slow flow phenomenon
por: Yasri, Sora, et al.
Publicado: (2018)

Activation of brain interleukin-1β in schizophrenia
por: Söderlund, J, et al.
Publicado: (2009)

Fulminant type 1 diabetes after COVID-19 vaccination
por: Tang, Xiaohan, et al.
Publicado: (2022)

COVID-19 infection in type 1 diabetes: emerging data
por: Miranda, Cesare, et al.
Publicado: (2021)

Genetic variations from successive whole genome sequencing during COVID-19 treatment in five individuals
por: Hemachudha, P., et al.
Publicado: (2022)

HSV1 viremia with fulminant hepatitis as opportunistic sequela in severe COVID-19
por: Roncati, Luca, et al.
Publicado: (2021)

Association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19
por: Tonon, David, et al.
Publicado: (2021)

The association of diabetes with COVID-19 disease severity: evidence from adjusted effect estimates
por: Liang, Xuan, et al.
Publicado: (2020)

Association with the actual blood group is the ONLY culprit in ABO and COVID-19 disease severity
por: Hajeer, Ali H., et al.
Publicado: (2023)

A role for interleukin-1 receptor antagonism in severe COVID-19?
por: Tattersall, Rachel S, et al.
Publicado: (2021)

Letter to the Editor on Type 1 diabetes onset triggered by COVID-19
por: Sholihah, Mentari Maratus, et al.
Publicado: (2021)

Interleukin 6 levels after tocilizumab administration in transplant recipients with COVID-19
por: Gade, Akhil R., et al.
Publicado: (2020)

Author’s Reply to: “Comment on: Pharmacokinetics and Safety of Recombinant Human Interleukin-1 Receptor Antagonist GR007 in Chinese Healthy Subjects”
por: Xie, Ran, et al.
Publicado: (2019)

Severity and 1-year cumulative incidence of COVID-19 among inpatients with haematologic malignancies
por: Ribeiro Baptista, J.P., et al.
Publicado: (2022)

Impact of blood type on thrombosis and disease severity in adult COVID-19 patients()
por: Rao, Shivani, et al.
Publicado: (2021)

Paradoxical Role of Interleukin-1R2 in Cardiovascular Disorders
por: Jadali, Zohreh
Publicado: (2023)

Autoimmune diseases are independently associated with COVID-19 severity: Evidence based on adjusted effect estimates
por: Yang, Haiyan, et al.
Publicado: (2021)

Novel heterozygous c.798C>G and c.1040T>G mutations in the GBA1 gene are associated with a severe phenotype of Gaucher disease type 1
por: Machaczka, Maciej, et al.
Publicado: (2014)

Interleukin-2-330T/G and Interleukin-10-1082A/G Genetic Polymorphisms and B-Cell Non-Hodgkin Lymphoma
por: Joob, Beuy, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_963hd554p6nqavjei028vrdqpg